<unk> , sold under the brand name Nuedexta, is a fixed-dose combination medication for the treatment of pseudobulbar affect (PBA). It contains<unk>  (DXM) and the class I antiarrhythmic agent<unk> .<unk>  was approved for medical use in the United States in October 2010, and is marketed by Avanir Pharmaceuticals.
Dextromethorphan/quinidine
Fentanyl/fluanisone
Bupivacaine/meloxicam
Oxycodone/naloxone
Desloratadine/pseudoephedrine
Pseudoephedrine/loratadine
Phenylephrine/ketorolac
Buprenorphine/naloxone